

## CURRICULUM VITAE

Name: Stanley Liauw, M.D.

Office Address:

University of Chicago  
Dept. of Radiation and Cellular Oncology  
5758 S Maryland Ave, MC 9006  
Chicago, IL 60637

Telephone #: (773) 702-6870  
Pager #: (773) 845-4304  
Fax #: (773) 834-7340

E-Mail: [sliauw@radonc.uchicago.edu](mailto:sliauw@radonc.uchicago.edu)

Medical License/Certification:

April 2006     State of Florida, ME95684  
May 2006     State of Illinois, 036-116022  
May 2006     DEA Number BL9731313  
June 2007     Board Certification in Radiation Oncology (American Board of Radiology)

Education:

Massachusetts Institute of Technology  
1993-1997, B.S. Chemical Engineering, Minor Biology, Cambridge, MA

University of Texas – Southwestern Medical School  
1997-2001, M.D., Dallas, TX

Postdoctoral Training:

Internship     Brigham and Women's Hospital, Harvard Medical School  
2001-2002, Internal medicine, Boston, MA

Residency     Shands Hospital, University of Florida College of Medicine  
2002-2006, Radiation Oncology, Gainesville, FL

Externships     Department of Radiation Oncology, Mt. Sinai School of Medicine  
11/2004, Intra-operatively planned prostate brachytherapy, NYC, NY

Department of Adult Clinical Oncology, Queen Elizabeth Hospital  
12/2004, Clinical Oncology elective, Hong Kong, China

Dept. of Radiation Oncology, Seattle Prostate Institute/Puget Sound VA  
2/2006, Low dose rate prostate brachytherapy, Seattle, WA

Department of Radiation Oncology, MD Anderson Cancer Center

4/2006, Gastrointestinal malignancies, Houston, TX

Coursework Stereotactic Body Radiation Therapy Training Program  
6/2015, University of Texas Southwestern Medical School, Dallas, TX

Positions and Appointments:

8/06-7/08 Clinical Instructor, Dept. of Radiation Oncology and Cellular Biology  
University of Chicago, Chicago, IL

7/08-6/12 Assistant Professor, Dept. of Radiation Oncology and Cellular Biology  
University of Chicago, Chicago, IL

7/12-present Associate Professor, Dept. of Radiation Oncology and Cellular Biology  
University of Chicago, Chicago, IL

Scientific and Medical Societies:

2005-2008 American Society of Clinical Oncology

2002-present American Society of Therapeutic Radiology and Oncology

Honors and Awards:

1996 Tau Beta Pi, National Engineering Honor Society

1997 Phi Beta Kappa (Top 5% of graduating class)

1997 Sigma Xi, National Scientific Research Society

1997-2001 Southwestern Medical Foundation Academic Scholarship

2005 Outstanding Resident Teaching Award, Univ. of Florida College of Medicine

2005 American Radium Society 87<sup>th</sup> Annual meeting Young Oncologist Award

2005 Radiological Society of North America Research Trainee Prize

2006 American Brachytherapy Society Seattle Prostate Institute Fellowship

2006 Outstanding Resident Teaching Award, Univ. of Florida College of Medicine

2006 Radiological Society of North America Research and Education Foundation,  
Roentgen Resident/Fellow Research Award

- 2007 Association of Residents in Radiation Oncology, Teacher of the Year Award, University of Chicago
- 2008 University of Chicago, Department of Radiation and Cellular Oncology, Samuel Hellman Outstanding Teacher of the Year Award
- 2008 ASCO/AACR Workshop: Methods in Clinical Cancer Research Fellow
- 2009 University of Chicago, Department of Radiation and Cellular Oncology, Samuel Hellman Outstanding Teacher of the Year Award
- 2011 Association of Residents in Radiation Oncology, Teacher of the Year Award, University of Chicago
- 2014 Association of Residents in Radiation Oncology, Teacher of the Year Award, University of Chicago

#### Extramural Professional Responsibilities

##### Journal Editorial Board:

Associate Editor (Gastrointestinal cancer), International Journal of Radiation Oncology, Biology, and Physics, 2013- present

##### Journal Review:

International Journal of Radiation Oncology, Biology, and Physics, 2006-present

Annals of Surgical Oncology, 2007-present

Current Medicine and Research Opinion, 2007-present

Journal of Urology, 2008-present

Journal of Oncology, 2008-present

Swiss Medical Weekly, 2008-present

Journal of Surgical Oncology, 2009-present

Journal of the National Medical Association, 2009-present

Technology in Cancer Research and Treatment, 2009-present

Nature Reviews Clinical Oncology, 2010-present

Cancer, 2010-present

British Journal of Cancer, 2010-present

Acta Pharmacologica Sinica, 2010-present

Practical Radiation Oncology, 2011-present

European Urology, 2012-present

Journal of Clinical Oncology, 2012-present

Prostate Cancer, 2013-present

American Journal of Clinical Oncology, 2014-present

New England Journal of Medicine, 2014-present

##### Scientific Program Committees:

Reviewer, Scientific abstracts, American Radium Society, 2006

Reviewer, Scientific abstracts, American Brachytherapy Society, 2010  
Reviewer, Scientific abstracts (GU), American Society of Radiation Oncology, 2011  
Reviewer, Scientific abstracts (GU), American Society of Radiation Oncology, 2012  
Reviewer, Scientific abstracts (GU), American Society of Radiation Oncology, 2013

Educational activities:

Item writer, Resident In-service Examination in Radiation Oncology: GU section, American College of Radiology, 2009-present  
Committee Member, American Board of Radiology Certification Examination (GU section, Item writer, oral board examiner), 2012  
Committee Member, American Board of Radiology Certification Examination (GU section, Oral board examiner), 2013  
Committee Member, American Board of Radiology Certification Examination (GU section, Oral board examiner), 2015

Invited presentations:

“Sublingual peptide drug delivery,” Division of pharmaceutical research and development, Hoffmann-LaRoche, Nutley, NJ, August 1994.

“Topics in cancer biology: metalloproteinase inhibitors and antisense oligonucleotides,” Division of oncology, Hoffmann-LaRoche, Nutley, NJ, August 1995.

“Drug delivery issues in solid tumors,” MIT-Harvard Department of Health Sciences Technology, Cambridge, MA, 1997.

“Salvage radiation therapy for biochemical failure after prostatectomy,” UT-Southwestern Medical School, Department of Radiation Oncology, Dallas, TX, May 2001.

“The importance of local control in inflammatory breast cancer,” University of Florida 33<sup>rd</sup> Annual Radiation Oncology Clinical Research Seminar, Gainesville, FL, Feb 2003.

“Using IV contrast in radiotherapy: rationale and considerations.” University of Florida 15<sup>th</sup> Annual Radiation Therapist Seminar, Gainesville, FL, February 2004.

“Does IV contrast influence dose calculations in IMRT head and neck treatment planning?” University of Florida 34<sup>th</sup> Annual Radiation Oncology Clinical Research Seminar, Gainesville, FL, February 2004.

“Does IV contrast influence dose calculations in IMRT head and neck treatment planning?” Joint Cancer Conference of the Florida Universities, 7<sup>th</sup> Annual Conference, Young Amgen Investigator Forum, Orlando, FL, February 2004.

“Hot topics in conformal head and neck radiotherapy.” Queen Elizabeth Hospital, Department of Clinical Oncology, Hong Kong SAR, China, December 2004.

“RT for node-positive SCCA of the head and neck: using post-treatment response to guide management of the neck.” University of Florida 35<sup>th</sup> Annual Radiation Oncology Clinical Research Seminar, Gainesville, FL, February 2005.

“The use of radiosensitizers in gastrointestinal malignancies.” Clinical training and development program, Hoffmann-LaRoche Pharmaceuticals, Nutley, NJ, February, March, and December 2005.

“Neck dissection after definitive radiation therapy for head and neck cancer: The use of computed tomography to manage the neck.” MD Anderson Cancer Center, April 2006.

“The role of adjuvant radiation therapy following robotic-assisted radical prostatectomy.” Robotic Prostatectomy: Expert Panel Review Course, Chicago, IL, March 2007 and June 2008.

“The Primary Treatment of Prostate Cancer with Radiation Therapy: An Overview.” Visiting Professor, Illinois Urologic Society Annual Meeting, Springfield, IL, September 12, 2008.

“The Role of Radiation Therapy after Radical Prostatectomy.” Visiting Professor, Illinois Urologic Society Annual Meeting, Springfield, IL, September 13, 2008.

“Innovations in Technology: Imaging of Prostate Cancer and Treatment with Radiation Therapy.” The University of Chicago Cancer Research Center Translational Seminar Series, Chicago, IL, November 14, 2008.

“Combined-Modality Therapy for Squamous Cell Carcinoma of the Anus: Past, Present, and Future.” University of Chicago Department of Surgery, Surgical Grand Rounds, Chicago, IL, December 9, 2009.

“Radiation therapy: Processes and Perspectives in the United States.” Department of Oncology, Gamma Knife Center at Hue University, Hue, Vietnam, February 10, 2010.

“GU Clinical and Translational Research: Radiation Oncology.” University of Chicago Department of Urology, Research seminar series, Chicago, IL, February 22, 2011.

“2011 Prostate Cancer Shootout.” The Chicago Urological Society, University Club of Chicago, Moderator for “External Beam Radiation Therapy,” Chicago, IL, March 12, 2011.

“Prostate cancer update 2011.” American Urological Association Annual Meeting, Faculty/Panelist for educational course led by William Catalona. Washington DC, May 17, 2011.

“Radiation therapy for prostate cancer: a refresher course.” Congreso Argentino De Radiologia (in partnership with the ASTRO Outreach Program and Sociedad Argentina de Radiologia), 57<sup>th</sup> Annual Meeting, Invited speaker, Buenos Aires, Argentina, September 9, 2011.

“RhoA mediates combined effects of irradiation and simvastatin.” Prostate Cancer Foundation, 18<sup>th</sup> Annual Scientific Meeting (Young Investigator Forum), Lake Tahoe, NV, September 21, 2011.

“Radiation Therapy Post-Radical Prostatectomy: Indications and Outcomes.” Update and Challenging Cases in Urologic Oncology. University of Chicago Department of Urology Symposium, Chicago, IL, October 29, 2011.

“Adjuvant Radiation Therapy vs. Salvage Radiation Therapy after Prostatectomy: A Debate.” Afternoon Program on Prostate Cancer (Guest Speaker: Alan Partin). Chicago Urological Society, Chicago, IL, November 9, 2011.

“The role of radiation therapy in R2 resection of colorectal cancer.” Controversies in Colon and Rectal Cancer Treatment. 3<sup>rd</sup> annual conference, University of Chicago, Chicago, IL, February 10, 2012.

“Prostate cancer update 2012.” American Urological Association Annual Meeting, Faculty/Panelist for educational course led by William Catalona. Atlanta GA, May 19-23, 2012.

“Radiation Therapy in Prostate Cancer: A practical review of institutional guidelines.” Department of Urology Resident and Fellow Lecture Series, Northwestern Memorial Hospital, Chicago, IL. July 26, 2012.

“Radiation Therapy in Prostate Cancer: A primer for urologists.” Urologic Grand Rounds, Northwestern Memorial Hospital, Chicago, IL. July 26, 2012.

“Defining the Role of Radiation Therapy for Unresectable Pancreatic Cancer.” GI symposium, University of Chicago, Chicago, IL, September 7, 2012.

“Combined Modality Therapy for Locally Advanced Rectal Cancer: An Evidence Based Review of the Current Standard of Care with RT.” Colorectal Cancer Grand Rounds, University of Chicago, Chicago, IL, November 13, 2012.

“Radiation Therapy for High-risk and Post-operative Prostate Cancer.” American Society of Radiation Oncology Spring Refresher Course, Chicago, IL, March 22, 2013.

“Prostate cancer update 2013.” American Urological Association Annual Meeting, Faculty/Panelist for educational course led by William Catalona. San Diego CA, May 7, 2013.

“How the outcomes research program at the University of Florida helped shaped the prostate cancer program at the University of Chicago.” 44<sup>th</sup> annual research seminar, Gainesville, FL, February 21, 2014.

“Radiation Therapy for High-risk and Post-operative Prostate Cancer.” American Society of Radiation Oncology Spring Refresher Course, Chicago, IL, March 9, 2014.

“Radiation Therapy for Prostate Cancer: An Introduction of Treatment Paradigms for a Developing Program.” Greater Horn Oncology Symposium, Moshi, Tanzania, March 25, 2014.

“Prostate cancer update 2014.” American Urological Association Annual Meeting, Faculty/ Panelist for educational course led by William Catalona. Orlando, FL, May 19, 2014

“Post-operative Radiation for Prostate Cancer: Controversies and Future Directions.” Stanford University Department of Radiation Oncology, November 10, 2014.

“Prostate cancer update 2015.” American Urological Association Annual Meeting, Faculty/ Panelist for educational course led by William Catalona. New Orleans, LA, May 18, 2015.

Visiting Professor in Radiation Oncology:

Stanford University, Department of Radiation Oncology, November 2014

Johns Hopkins University, Department of Radiation Oncology, April 2015

UT Southwestern, Department of Radiation Oncology, June 2015

State University of New York – Buffalo, Department of Radiation Oncology, September 2015 (anticipated)

Committee Assignment:

2001-2002	Selection Committee for Internal Medicine residency applicants, Brigham and Women’s Hospital, Boston, MA
2002-2006	Selection Committee for Radiation Oncology residency applicants, University of Florida, Gainesville, FL
2005-2006	Speaker Bureau, Division of Clinical Training and Development, Hoffmann-LaRoche, Nutley, NJ
2005-2006	Chief Resident, Radiation Oncology, University of Florida
2007-2012	Quality chair, Department of Radiation and Cellular Oncology, University of Chicago, Chicago IL

Languages:

Spoken: English, Spanish (conversational)  
Studied: French, Mandarin, Indonesian

Marital Status: Married  
Dependents #: None

Military Services: None

Publications (peer reviewed articles):

1. Costantino H, **Liauw S**, Mitragotri S, Langer R, Klivanov A, Sluzky V. The pharmaceutical development of insulin: historical perspectives and future directions. In: Shahrokh Z, Sluzky V, Cleland JL, Shire SJ, Randolph TW, editors. Therapeutic protein and peptide formulation and delivery, American Chemical Society Symposium Series, vol. 675. Washington DC: American Chemical Society; 1997. p. 29-66.
2. **Liauw SL**. Temperature-induced alteration of skin permeability for drug delivery applications. Undergraduate thesis, Department of Chemical Engineering and Harvard-MIT Department of Health Sciences Technology. Cambridge (MA): MIT; 1997.
3. **Liauw SL**, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy after biochemical failure of radical prostatectomy: single-institution experience. Urology 61(6):1204-10, 2003.
4. **Liauw SL**, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast cancer: outcomes with trimodality therapy for non-metastatic disease. Cancer 100(5):920-8, 2004.
5. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, **Liauw SL**, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Journal of the American Medical Association 291(11):1325-1332, 2004.
6. **Liauw SL**, Amdur RJ, Palta JR, Mendenhall WM, Kim S. The effect of intravenous contrast on intensity modulated radiation therapy dose calculations for head and neck cancer. American Journal of Clinical Oncology, 28(5):456-459, 2005.
7. **Liauw SL**, Mancuso AA, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Post-radiotherapy neck dissection for lymph-node positive head and neck cancer: using computed tomography to manage the neck. Journal of Clinical Oncology, 24(9):1421-1427, 2006.
8. **Liauw SL**, Sylvester JE, Blasko JC, Grimm PD. Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. International Journal of Radiation Oncology Biology Physics, 66(3): 669-673, 2006.
9. **Liauw SL**, Mancuso AA, Amdur RJ, Mendenhall WM. Radiographic response of retropharyngeal nodes after radiation therapy: an incomplete response does not necessarily indicate failure. International Journal of Radiation Oncology Biology Physics, 66(4):1017-1021, 2007.



10. **Liauw SL**, Yeh AM, Morris CG, Olivier K, Mendenhall NP. Whole abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. International Journal of Radiation Oncology Biology Physics, 66(5):1440-1445, 2006.
11. **Liauw SL**, Byer J, Yachnis T, Morris CG, Amdur RJ, Mendenhall WM. Radiotherapy after subtotally-resected or recurrent ganglioglioma. International Journal of Radiation Oncology Biology Physics, 67(1):244-247, 2007.
12. **Liauw SL**, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head and Neck, 29(8):715-19, 2007.
13. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Kupelian PA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, **Liauw SL**, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology, 25(15): 2035-41, 2007.
14. Jani AB, **Liauw SL**, Blend MJ. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clinical Medicine and Research, 5(2): 123-31, 2007.
15. Jani AB, Master VA, Rossi PJ, **Liauw SL**, and Johnstone PAS. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer and Prostatic Diseases, 10:347-51, 2007.
16. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, **Liauw SL**, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. Journal of Clinical Oncology, 25(29):4581-6, 2007.
17. Yeung AR, **Liauw SL**, Amdur RJ, Mancuso AA, Hinerman RW, Morris CG, Villaret DB, Werning JW, Mendenhall WM. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer, 112(5):1076-82, 2008.
18. **Liauw SL**, Minsky BD. The use of capecitabine in the combined-modality therapy of rectal cancer. Review. Clinical Colorectal Cancer, 7(2):99-104, 2008.
19. **Liauw SL**, Weichselbaum RR, Zagaja GP, Jani AB. Salvage radiotherapy after post-prostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? International Journal of Radiation Oncology Biology Physics, 71(5):1316-21, 2008.
20. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, **Liauw SL**, Kestin LL, Deweese TL, Scardino PT, Stephenson

AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 72(6):1298-302, 2008.

21. Jani AB, Johnstone PA, **Liauw SL**, Master VA, Brawley OW. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. American Journal of Clinical Oncology. 31(4):375-8, 2008.

22. Gutt R, **Liauw SL**, Weichselbaum RR. Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Review. Nature Clinical Practice: Gastroenterology and Hepatology, 6(1):38-46, 2009.

23. **Liauw SL**, Fricano J, Correa D, Weichselbaum RR, Jani AB. Dose-Escalated Radiation Therapy for Intermediate-Risk Prostate Cancer: Patient Selection for Androgen Deprivation Therapy using Percent Positive Cores. Cancer, 115(8):1784-90, 2009.

24. **Liauw SL**, Weichselbaum RR, Rash C, Correa D, Al-Hallaq HA, Pelizzari CA, Jani AB. Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer. Technology in Cancer Research and Treatment, 8(3):201-6, 2009.

25. Choe KS, Jani AB, **Liauw SL**. External Beam Radiotherapy for Prostate Cancer Patients on Anticoagulation Therapy: How Significant is the Bleeding Toxicity? International Journal of Radiation Oncology, Biology, Physics, 76(3):755-60, 2010.

26. **Liauw SL**, Stadler WM, Correa D, Weichselbaum RR, Jani AB. Dose Escalated Radiation Therapy for High Risk Prostate Cancer: Outcomes in the Modern Era with Short Term Androgen Deprivation Therapy. International Journal of Radiation Oncology, Biology, Physics, 76(3):755-60, 2010.

27. Jani AB, Johnstone PA, **Liauw SL**, Master VA, Rossi PJ. Prostate Cancer Modality Time Trend Analyses From 1973 to 2004: A Surveillance, Epidemiology, and End Results Registry Analysis. American Journal of Clinical Oncology, 33(2):168-72, 2010.

28. Kalakota K, Rakhno E, Pelizzari CA, Jani AB, **Liauw SL**. Late rectal toxicity after prostate brachytherapy: Influence of supplemental external beam radiation on dose-volume histogram analysis. Brachytherapy, 9(2):131-6, 2010.

29. Choe KS, Correa D, Jani AB, **Liauw SL**. Use of Anticoagulants Improves Biochemical Control of Localized Prostate Cancer Treated with Radiotherapy. Cancer, 116(7):1820-6, 2010.

30. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, **Liauw SL**. Statin Use and Risk of Prostate Cancer Recurrence in Men Treated with Radiation Therapy. Journal of Clinical Oncology, 28(16):2653-9, 2010.

31. Devisetty K, Zorn KC, Katz MH, Jani AB, **Liauw SL**. External Beam Radiation Therapy After Transurethral Resection of the Prostate: A Report on Acute and Late Genitourinary Toxicity. International Journal of Radiation Oncology, Biology, Physics, 77(4):1060-5, 2010.
32. Gutt R, **Liauw SL**, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Review. Nature Clinical Practice: Gastroenterology and Hepatology, 7(8):437-47, 2010.
33. Terakedis BE, Rossi PJ, **Liauw SL**, Johnstone PA, Jani AB. A Surveillance, Epidemiology, and End Results (SEER) Registry Analysis of Prostate Cancer Modality Time Trends by Age. American Journal of Clinical Oncology, 33(6):619-23, 2010.
34. Choe KS, **Liauw SL**. Radiotherapeutic Strategies in the Management of Low-Risk Prostate Cancer. The Scientific World Journal, 10:1854-69, 2010.
35. Malik R, Jani AB, **Liauw SL**. PSA Halving-Time while on Neoadjuvant Androgen Deprivation Therapy is Associated with Biochemical Control in Men Treated with Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 79(4):1022-8, 2011.
36. Malik R, Jani AB, **Liauw SL**. External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men with High International Prostate Symptom Scores. International Journal of Radiation Oncology, Biology, Physics, 80(4):1080-6, 2011.
37. **Liauw SL**, Liauw SH. Prolongation of Total Treatment Time Due to Infrequently Missed Days of Treatment is Not Associated with Inferior Biochemical Outcome After Dose-Escalated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 81(3):751-7, 2011.
38. Pederson AW, Fricano J, Correa D, Pelizzari CA, **Liauw SL**. Late Toxicity after Intensity Modulated Radiation Therapy for Localized Prostate Cancer: An Exploration of Dose-Volume Histogram Parameters to Limit Genitourinary and Gastrointestinal Toxicity. International Journal of Radiation Oncology, Biology, Physics, 82(1):235-41, 2012.
39. Solanki AA, **Liauw SL**. The Role of HMG-CoA Reductase Inhibitors with Curative Radiotherapy in Men with Prostate Cancer. Research and Reports in Urology, June 14, 2011.
40. Song S, Yenice KM, Kopec M, **Liauw SL**. Image-Guided Radiotherapy Using Surgical Clips as Fiducial Markers after Prostatectomy: A Report of Total Setup Error, Required PTV Expansion, and Dosimetric Implications. Radiotherapy and Oncology, 103(2):270-4, 2012.
41. Edelman S, **Liauw SL**, Rossi PJ, Cooper S, Jani AB. High-Dose Radiotherapy with or without Androgen Deprivation Therapy for Intermediate Risk Prostate Cancer: Cancer Control and Toxicity Outcomes. International Journal of Radiation Oncology, Biology, Physics, 83(5):1473-9, 2012.

42. Ranck MC, Corbin KS, Golden DW, **Liauw SL**, Weichselbaum RR, Salama JK. Hypofractionated Image-guided Radiation Therapy in the Treatment of Oligometastatic Renal Cell Carcinoma. American Journal of Clinical Oncology, E pub Aug 2 2012.
43. Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, **Liauw SL**. Combined modality therapy for rectal cancer: the relative value of post-treatment vs. pre-treatment CEA as a prognostic marker for disease recurrence. Annals of Surgical Oncology, 19(8):2471-6, 2012.
44. Lee AY, Wu T, Vannier MW, Testa G, **Liauw SL**. Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. Journal of Gastrointestinal Cancer, Apr 11, 2012.
45. **Liauw SL**, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. Evaluation of the Prostate Bed for Local Recurrence after Radical Prostatectomy using Endorectal MRI. International Journal of Radiation Oncology, Biology, Physics, 85(2):378-84, 2013.
46. Tonlaar N, Song S, Hong JC, Minsky BD, Chang DT, Polite BN, **Liauw SL**. Combined Modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race. American Journal of Clinical Oncology, 37(2):122-5, 2014.
47. Corbin KS, Kunnavakkam R, Eggener SE, **Liauw SL**. Intensity Modulated Radiation Therapy after Radical Prostatectomy: No Decline in Urinary, Gastrointestinal, or Sexual Quality of Life with Early Follow-up. Practical Radiation Oncology, 3(2):138-44, 2012.
48. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, **Liauw SL**. Aspirin Use and the Risk of Prostate Cancer Mortality in Men Treated with Prostatectomy or Radiotherapy. Journal of Clinical Oncology, 30(28):3540-4, 2012.
49. Validation of Normal Tissue Complication Probability Predictions in Individual Patient: Late Rectal Toxicity. Semenenko VA, Tarima SS, Devisetty K, Pelizzari CA, **Liauw SL**. International Journal of Radiation Oncology, Biology, Physics, 85(4):1103-9, 2013.
50. Golden DW, Novak CJ, Minsky BD, **Liauw SL**. Radiation dose  $\geq$ 54 Gy and CA 19--9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiation Oncology, 7(1):156, 2012.
51. Choe KS, **Liauw SL**. Possible Therapeutic Effects of Aspirin on Carcinogenesis and Cancer Therapy. Editorial. Expert Review of Anticancer Therapy, 13(2):115-7, 2013.
52. **Liauw SL**, Connell PP, Weichselbaum RR. New paradigms and future challenges in Radiation Oncology: An Update of Biological Targets and Technology. State of the Art Review. Science: Translational Medicine, 5(173):1-18, 2013.

53. Kalakota K, **Liauw SL**. Toxicity After External Beam Radiation Therapy for Prostate Cancer: An Analysis of Late Morbidity in Men with Diabetes Mellitus. Urology, 81(6):1196-201, 2013.

54. Macomber M, Mullane KM, **Liauw SL**. Herpes Zoster and Radiation Therapy: What Radiation Oncologists Need to Know about Diagnosing, Preventing, and Treating Herpes Zoster. Practical Radiation Oncology, E pub 2013 Mar 27.

55. Solanki AA, **Liauw SL**. Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer, 119(15):2807-14, 2013.

56. Solanki AA, Chang DT, **Liauw SL**. Future Directions in Combined Modality Therapy for Rectal Cancer: Re-evaluating the Role of Total Mesorectal Excision After Chemoradiotherapy. Oncotargets and Therapy, 6:1097-110, 2013.

57. Liu GF, Bair RJ, Bair E, **Liauw SL**, Koshy M. Clinical Outcomes for Gastric Cancer following Adjuvant Chemoradiation Utilizing Intensity Modulated versus Three-Dimensional Conformal Radiotherapy. PLoS One, 9(1):e82642, 2014.

58. Chennupati SK, Pelizzari CA, Kunnavakkam R, **Liauw SL**. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med, 3(4):954-61, 2014.

59. Corbin KS, Kindler HL, **Liauw SL**. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther, May 12;7:713-8, 2014.

60. Chang DT, Brunner T, Cheng JC, **Liauw S**, Meyer J, Wo J. Oncology scan-novel treatment strategies for gastrointestinal cancers. International Journal of Radiation Oncology, Biology, Physics, 89(4):699-703, 2014.

61. Son CH, Hamstra DA, Feng FY, **Liauw SL**. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir  $\leq 0.2$  to Select Men for Short-term Hormonal Therapy. American Journal of Clinical Oncology, E pub, 2014 Dec 6.

62. Son CH, Chennupati SK, Kunnavakkam R, **Liauw SL**. The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. E pub, 2014 Dec 6

62. Kumar KA, Wu T, Tonlaar N, Stepaniak C, Yenice KM, **Liauw SL**. Image-guided radiation therapy for prostate cancer: A computed tomography-based assessment of fiducial marker migration between placement and 7 days. Pract Radiat Oncol. E pub, 2014 Dec 24.

63. Chang DT, Brunner T, Chia-Hsien Cheng J, **Liauw SL**, Meyer J, Wo JY. Randomized Trials and New Directions in Gastrointestinal Cancer. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):459-64.

64. Ying J, Wang CJ, Yan J, **Liauw SL**, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. Epub, 2015 Jul 9.

65. Pearce SM, **Liauw SL**, Eggener SE. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug;42(3):287-98.

Book chapters:

1. **Liauw SL** (section editor): Difficult cases in Prostate Cancer. In: Small W (ed), Difficult cases in Radiation Oncology. Demos Medical, New York, 2012 (in press).

Abstracts:

1. Webster WS, **Liauw SL**, McConnell J, Sagalowsky A, Roehrborn CG. Radiation therapy for salvage treatment of local prostatectomy failure. **Poster**. American Urologic Association, 96<sup>th</sup> Annual meeting Anaheim, CA, June 2001.
2. **Liauw SL**, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast cancer: outcomes with trimodality therapy. **Poster**. Radiological Society of North America, 89<sup>th</sup> Scientific assembly and annual meeting, Chicago, IL, November 2003.
3. **Liauw SL**, Kim S, Mendenhall WM, Amdur RJ. Don't be afraid to use intravenous contrast when planning conformal head and neck radiotherapy. **Poster**. American Radium Society, 86<sup>th</sup> annual meeting, Napa Valley, CA, May 2004.
4. **Liauw SL**, Kim S, Amdur RJ. Dosimetric consequences of a shrinking neck node: Is replanning necessary with IMRT? **Oral presentation**. Radiological Society of North America, 90<sup>th</sup> annual meeting, Chicago, IL, December 2004.
5. **Liauw SL**, Amdur RJ, Morris CG, Mendenhall WM. Is a negative CT four weeks after radiotherapy as good as a negative neck dissection in patients with head and neck cancer? **Oral presentation** (Travel grant). American Radium Society, 87<sup>th</sup> annual meeting Barcelona, Spain, May 2005.
6. **Liauw SL**, Amdur RJ, Morris CG, Mancuso AA, Mendenhall WM. Complete response after definitive radiotherapy for node-positive head and neck cancer: the use of post-treatment physical exam versus computed tomography in the management of the neck. **Poster Discussion**. American Society of Therapeutic Radiation Oncology 47<sup>th</sup> annual meeting, Denver, CO, October 2005.
7. **Liauw SL**, Morris CG, Amdur RJ, Mendenhall WM, Mancuso AA. Using post-treatment computed tomography to guide the decision of neck dissection after radiotherapy for head and neck cancer: the significance of focally abnormal nodes. **Oral presentation**,

Neuroradiology: Lymph nodes (Resident training prize). Radiological Society of North America, 91<sup>st</sup> annual meeting, Chicago, IL, December 2005.

8. **Liauw SL**, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Salvage neck dissection of isolated neck recurrence after definitive radiotherapy for head and neck cancer. **Poster**. American Radium Society, 88<sup>th</sup> annual meeting, Hawaii, May 2006.
9. **Liauw SL**, Sylvester JE, Morris CG, Blasko JC, Grimm PD. Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. **Poster**. American Society of Therapeutic Radiation Oncology 48<sup>th</sup> annual meeting, Philadelphia, PA, November 2006.
10. **Liauw SL**, Mancuso AA, Amdur RJ, Mendenhall WM. Radiographic response of retropharyngeal nodes after radiation therapy. **Oral presentation**, Neuroradiology: Lymph nodes. Radiological Society of North America, 92<sup>nd</sup> annual meeting, Chicago, IL, December 2006.
11. **Liauw SL**, Zagaja GP, Weichselbaum RR, Jani AB. Salvage RT after post-prostatectomy biochemical failure: outcomes for patients with no extraprostatic disease with radioimmunoscinigraphy. **Poster**. American Society of Clinical Oncology, Prostate cancer symposium, Orlando, FL, February 2007.
12. **Liauw SL**, Weichselbaum RR, Jani AB. Intensity-Modulated Radiation Therapy for localized prostate cancer: preliminary results with a minimum 3 years of follow-up. **Poster**. American Radium Society, 89<sup>th</sup> annual meeting, Amsterdam, May 2007.
13. Malik R, Jani AB, Cloutier D, **Liauw SL**. Can external beam radiotherapy for prostate cancer help improve urinary symptoms in men with high IPSS scores? **Oral presentation**. American Society of Therapeutic Radiation Oncology 49<sup>th</sup> annual meeting, Los Angeles, CA, October 2007.
14. Choe KS, Jani AB, **Liauw SL**. Should radiation therapy be modified for prostate cancer patients on anticoagulants? **Poster**. American Society of Therapeutic Radiation Oncology 49<sup>th</sup> annual meeting, Los Angeles, CA, October 2007.
15. Devisetty K, Jani AB, Choe KS, **Liauw SL**. Should prior TURP influence the decision to treat prostate cancer with external beam radiation therapy? **Poster**. American Society of Therapeutic Radiation Oncology 49<sup>th</sup> annual meeting, Los Angeles, CA, October 2007.
16. Yeung AR, **Liauw SL**, Amdur RJ, Mancuso A, Hinerman R, Villaret DB, Werning JW, Morris CG, Mendenhall WM. Lymph node-positive head and neck cancer treated with primary radiotherapy: can treatment response determine the extent of neck dissection? **Oral presentation**. American Society of Therapeutic Radiation Oncology 49<sup>th</sup> annual meeting, Los Angeles, CA, October 2007.
17. **Liauw SL**, Jani AB, Fricano J, Rash C, Pelizzari CA, Weichselbaum RR. Salvage RT for biochemical failure post-prostatectomy: Do we reduce or increase toxicity of treatment with

IMRT? **Poster.** American Society of Therapeutic Radiation Oncology 49<sup>th</sup> annual meeting, Los Angeles, CA, October 2007.

18. **Liauw SL**, Rakhno E, Pelizzari CA, Jani AB. Toxicity after prostate brachytherapy with or without supplemental external beam radiation therapy. **Abstract.** Genitourinary cancers symposium, San Francisco, CA, February 2008.

19. Malik R, Jani AB, **Liauw SL**. PSA “Halving-Time,” during Neoadjuvant Androgen Deprivation Therapy and Prior to Radiotherapy is associated with Biochemical Control. **Oral presentation.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

20. Gutt R, Weichselbaum RR, **Liauw SL**. Association of Statins with Biochemical Failure after Radiotherapy for Prostate Cancer. **Poster.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

21. **Liauw SL**, Correa D, Jani AB. Intermediate-Risk Prostate Cancer and Dose Escalated Radiation Therapy: Selection of Patients for Androgen Deprivation Therapy using Percent Positive Cores. **Poster.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

22. Havnen A, **Liauw SL**, Pelizzari CA, Yenice K. Image-guided radiotherapy to the prostate after implantation of gold fiducials: Is it necessary to wait 7 days for planning? **Poster.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

23. Grossman C, Minsky BD, **Liauw SL**. Acute and Late Toxicity of Radiotherapy for Rectal cancer in Patients with Inflammatory Bowel Disease. **Poster.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

24. Jani AB, Johnstone PA, **Liauw SL**, Master V, Rossi P. Prostate Cancer Modality Time Trend Analyses from 1973-2004: A Surveillance, Epidemiology, and End Results (SEER) Registry Analysis. **Oral presentation.** American Society of Therapeutic Radiation Oncology 50<sup>th</sup> annual meeting, Boston, MA, September 2008.

25. **Liauw SL**, Stadler WM, Correa D, Weichselbaum RR, Jani AB. Dose Escalated Radiation Therapy for High Risk Prostate Cancer: Outcomes in the Modern Era with Short Term Androgen Deprivation Therapy. **Poster.** American Society of Therapeutic Radiation Oncology 51<sup>st</sup> annual meeting, Chicago, IL, November 2009.

26. Gutt R, Tonlar N, Weichselbaum RR, Karrison T, Kunnavakkam R, **Liauw SL**. Association of LDL Levels with Biochemical Failure after Radiotherapy for Prostate Cancer. **Oral presentation.** American Society of Therapeutic Radiation Oncology 51<sup>st</sup> annual meeting, Chicago, IL, November 2009.

27. Song S, Yenice KM, Wiersma R, **Liauw SL**. Image-guided Radiotherapy after Radical Prostatectomy: A Report of Total Setup Error Using Surgical Clips as Fiducials. **Poster.**



American Society of Therapeutic Radiation Oncology 51<sup>st</sup> annual meeting, Chicago, IL, November 2009.

28. Wu T, Kopec M, **Liauw SL**, Yenice KM. Can SBRT of 45 Gy in 3 Fractions Be Safely Delivery to Unresectable Pancreas Cancer Patients? **Poster**. American Society of Therapeutic Radiation Oncology 51<sup>st</sup> annual meeting, Chicago, IL, November 2009.

29. Choe KS, Correa D, Jani AB, **Liauw SL**. Use of Anticoagulants Improves Biochemical Control of Localized Prostate Cancer Treated with Radiotherapy. **Poster**. American Society of Therapeutic Radiation Oncology 51<sup>st</sup> annual meeting, Chicago, IL, November 2009.

30. Corbin K, Pederson A, Pelizzari CA, Liauw SL. Long term toxicity of whole pelvic radiation therapy. **Oral presentation**, Radiation Oncology. Radiological Society of North America, 95<sup>th</sup> annual meeting, Chicago, IL, December 2009.

31. Pederson A, Corbin K, Pelizzari CA, **Liauw SL**. Late Toxicity after Intensity Modulated Radiotherapy for Localized Prostate Cancer: DVH Guidelines for Gastrointestinal and Genitourinary Morbidity. **Poster**. American Radium Society, 92<sup>nd</sup> annual meeting, Cancun, Mexico, May 2010.

32. Malik R, **Liauw SL**. Influence of Time to Radiotherapy after Biopsy on Biochemical Control in Men with Localized Prostate Cancer. **Poster**. American Radium Society, 92<sup>nd</sup> annual meeting, Cancun, Mexico, May 2010.

33. Kalakota K, Rakhno E, Pelizzari CA, Jani AB, **Liauw SL**. Late Rectal Toxicity after Prostate Brachytherapy: Influence of Supplemental External Beam Radiation on Dose Volume Histogram Analysis. **Poster**. American Radium Society, 92<sup>nd</sup> annual meeting, Cancun, Mexico, May 2010.

34. **Liauw SL**, Correa D. Missed days of treatment are not associated with inferior biochemical outcome with external beam radiation therapy for prostate cancer. **Poster**. American Radium Society, 92<sup>nd</sup> annual meeting, Cancun, Mexico, May 2010.

35. **Liauw SL**, Song S, Tonlaar N, Hong JC, Minsky BD, Chang DT, Polite B. Combined Modality Therapy For Rectal Cancer: Analysis Of Potential Differences In Disease Presentation, Treatment Adherence, And Treatment Outcome According To Race. **Poster Discussion**. American Society of Therapeutic Radiation Oncology 52<sup>nd</sup> annual meeting, San Diego, CA, October 2010.

36. Choe KS, Cowan JE, Carroll PR, D'Amico AV, **Liauw SL**. Aspirin Use and the Risk of Prostate Cancer Death in Men Treated with Prostatectomy or Radiotherapy: Results from the CaPSURE Database. **Oral presentation**. American Society of Therapeutic Radiation Oncology 52<sup>nd</sup> annual meeting, San Diego, CA, October 2010.

37. Golden DW, Novak CJ, Minsky BD, **Liauw SL**. Radiation dose  $\geq 54$  Gy is associated with improved survival for unresectable pancreatic cancer. **Poster**. American Society of Therapeutic Radiation Oncology 52<sup>nd</sup> annual meeting, San Diego, CA, October 2010.

38. Song S, Polite B, Minsky BD, **Liauw SL**. Post-treatment CEA values, and CEA trends at the time of uncertain post-treatment imaging, have prognostic value after combined modality therapy for rectal cancer. **Poster**. American Society of Therapeutic Radiation Oncology 52<sup>nd</sup> annual meeting, San Diego, CA, October 2010.
39. Novak C, Golden D, **Liauw SL**. Outcomes of definitive chemoradiation for squamous cell carcinoma of the anus and the effect of radiation technique on hematologic parameters. **Poster**. GI ASCO symposium, San Francisco, CA, January 2011.
40. Pitroda SP, Gutt R, Vannier MW, Oto A, **Liauw SL**. A Study of Endorectal MRI in the Evaluation of a Detectable PSA Post-Prostatectomy: PSA Level and Time to PSA Recurrence are Associated With the Presence of Locally Recurrent Disease. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
41. Gutt R, Dess RT, Pitroda SP, Vannier MW, Oto A, Liauw SL. Endorectal MRI And Treatment Planning Considerations In Intact Prostate Cancer: Which Patients Are At Greatest Risk For Radiographic Seminal Vesicle Involvement? **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
42. Corbin KS, Kunnavakkam R, **Liauw SL**. Assessment of Urinary Quality of Life Using a Validated Questionnaire: Post Prostatectomy Radiation Does Not Adversely Affect Urinary Continence. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
43. Osmundson EC, Kunnavakkam R, **Liauw SL**. Biochemical Failure After Radiation Therapy for Prostate Cancer: An Analysis of Risk Factors for Progression Including Comorbidity Index. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
44. Kalakota K, Correa D, **Liauw SL**. Do diabetic patients experience more toxicity after external beam radiation therapy for prostate cancer? **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
45. Solanki AA, Correa D, **Liauw SL**. Active tobacco use may promote late genitourinary toxicity after radiotherapy for prostate cancer. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
46. Hasselle MD, Salama JK, Tye1 KE, Golden DW, Liauw SL, Weichselbaum RR, Malik R. Patterns Of Progression Following Hypofractionated Image-guided Radiotherapy to Abdominal Lymph Nodes In Oligometastatic Patients. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.
47. Gutt R, **Liauw SL**, Beckett M, Liang H, Perakis S, Filippo M, Pitroda SP, Darga T, Khodarev NN, Weichselbaum RR. Statin Therapy for Prostate Cancer: Understudied and

Underutilized. **Poster**. American Society of Therapeutic Radiation Oncology 53<sup>rd</sup> annual meeting, Miami, FL, October 2011.

48. **Liauw SL**, Stephens KU. Outcomes after ‘early’ salvage RT for biochemically recurrent prostate cancer: support for aggressive local-regional therapy for a post-op PSA  $\leq 0.5$ . American Radium Society 94<sup>th</sup> annual meeting, Las Vegas, NV, May 2012.

49. Ofor O, **Liauw SL**. PSA Halving time of  $\leq 2$  weeks and post-RT PSA Nadir  $< 0.1$  ng/ml are associated with excellent biochemical control for high-risk prostate cancer: Implications regarding the need for long term ADT with dose escalated RT. **Poster**. American Society of Therapeutic Radiation Oncology 54<sup>th</sup> annual meeting, Boston, MA, October 2012.

50. Kumar K, Wu T, **Liauw SL**. Evaluation of Gold Fiducial Marker Migration After Implantation in Prostate Image-Guided Radiotherapy (IGRT). **Poster**. American Society of Therapeutic Radiation Oncology 54<sup>th</sup> annual meeting, Boston, MA, October 2012.

51. Ranck M, **Liauw SL**. Refining intermediate risk prostate cancer: An Analysis of Prostate Biopsy Pathology and Implications for Hormone Therapy with dose escalated radiation therapy. **Poster**. American Society of Therapeutic Radiation Oncology 54<sup>th</sup> annual meeting, Boston, MA, October 2012.

52. Liu GF, Bair RJ, Bair E, Liauw SL, Koshy M. Clinical Outcomes for Gastric Cancer Following Adjuvant Chemoradiation Utilizing Intensity Modulated Radiation Therapy. **Poster**. American Society of Therapeutic Radiation Oncology 54<sup>th</sup> annual meeting, Boston, MA, October 2012.

53. **Liauw SL**, Stephens KU. Salvage Radiation Therapy After Postprostatectomy Failure: Benefits of Hormonal Therapy and Pelvic Nodal Radiation Are Not Necessarily Limited to “High-Risk” Cases. **Poster**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

54. Parekh A, Ranck MC, Chennupati SK, Eggen SE, **Liauw SL**. No Difference in Late Toxicity With Postoperative Radiation Therapy Following Open or Robotic Prostatectomy. **Poster**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

55. Parekh A, Ranck MC, Chennupati SK, **Liauw SL**. Gastrointestinal and Genitourinary Toxicity and Quality of Life After Postprostatectomy Radiation Therapy: Are Normal Tissue DVH Parameters for Intact Prostate Cancer Applicable? **Poster**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

56. Chennupati SK, Pelizzari CA, Kunnavakkam R, **Liauw SL**. Late Gastrointestinal and Genitourinary Toxicity and Quality of Life After Treatment for Localized Prostate Cancer: Redefining Optimal Rectal DVH Parameters for Intensity Modulated Radiation Therapy. **Poster discussion**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

57. Son CH, Chennupati SK, **Liauw SL**. The Impact of Hormonal Therapy on Sexual Quality of Life in Men Receiving Intensity Modulated Radiation Therapy for Prostate Cancer. **Poster**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

58. Son CH, Hamstra DA, Feng FY, **Liauw SL**. High-Risk Prostate Cancer Treated With Dose-Escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir  $\leq 0.2$  to Select Men for Short-term Hormonal Therapy. **Poster discussion**. American Society of Therapeutic Radiation Oncology 55<sup>th</sup> annual meeting, Atlanta, GA, September 2013.

Non-academic recognition:

1. Performed in Weill Recital Hall at Carnegie Hall eight times as winner of tri-state area competitions in piano duets and popular piano styles, 1986-1993.
2. Qualified for New England Championships, Varsity Swimming, MIT, 1995.

Funding:  
*ACTIVE*

Departmental funding (Liauw) 8/15/2006 – present  
Radiation therapy for prostate cancer: Dosimetric and clinic outcomes in the IMRT era  
All prostate cancer patients treated at the University of Chicago dating back to 1988 are prospectively followed in this outcomes study, to see how clinical and technical parameters affect disease control and quality of life.

*COMPLETED*

P50 CA090386 NIH/NCI	Site PI: Stadler	06/01/01-01/31/14 \$145,141	1.20 calendar
-------------------------	------------------	--------------------------------	---------------

*SPORE in Prostate Cancer\**

This is an NCI sponsored organ-specific program project designed to further understanding and treatment of prostate cancer. The University of Chicago investigators are full collaborators on all aspects of the SPORE, provide leadership on the executive committee, and lead a project. Project goals include viral based TNF- $\alpha$  therapy in combination with radiotherapy to enhance treatment of high risk localized prostate cancer, an in vivo study exploring methods to enhance the TNF- $\alpha$  radiosensitization through modulation of the NFkB pathway, and the study of STAT1 as a predictive marker for radiation resistance in prostate cancer.

\*In collaboration with Northwestern University

Prostate Cancer Foundation	PI: Liauw	01/01/10-12/31/12 \$75,000	1.39 calendar
----------------------------	-----------	-------------------------------	---------------

*Targeting the Lipid Biosynthesis Pathway to Improve Radiotherapeutic Outcomes: Potential Role of Statins in the Management of Prostate Cancer*

Based on analysis of clinical outcomes demonstrating a possible radiosensitizing effect of statins on radiation therapy for prostate cancer, a laboratory collaboration was initiated in the Weichselbaum lab. The preliminary goals are to characterize this possible effect in vitro with dose response curves.

R01 CA120540-01A2    PI: Pan                      07/27/07-05/31/12                      0.47 calendar  
NIH/NCI    \$250,000

*Optimized Cone-Beam CT for Image-Guided Radiation Therapy*

The broad objective of the project is to using the on-board imager as the test-bed platform, capitalize fully on the hardware capabilities and on the recent algorithm advances through developing innovative scanning configurations and algorithms to yield accurate and dose-efficient volumetric images in IGRT.

*PENDING*

None

*OVERLAP*

None.

Ongoing studies with Institutional Review Board approval, PI: Liauw

*Retrospective*

1. Radiotherapy for Prostate Cancer: Dosimetric and Clinical outcomes in the conventional, conformal, and IMRT eras (University of Chicago IRB #14934-A)
2. Evaluation of STAT1 and mcl-1 as predictive markers for radiotherapy outcomes in prostate cancer (University of Chicago IRB #15609-B)
3. Combined modality therapy for rectal cancer: clinical outcomes after radiation therapy (University of Chicago IRB #16039-B)
4. Clinical Outcomes after Radiation Therapy for Pancreatic cancer (University of Chicago IRB #10102-B)
5. Evaluation of endorectal MRI for risk stratification, treatment planning, and workup after biochemical failure in patients with adenocarcinoma of the prostate (University of Chicago IRB# 110061)
6. Long Term Database Collection for Renal Cell Carcinoma (University of Chicago IRB# 110062)
7. Long Term Database Collection for Anal Cancer (University of Chicago IRB# 14-0099)

*Prospective – Investigator initiated, original protocols*

1. A Phase I Study of Stereotactic Body Radiation Therapy in Patients with Unresected Adenocarcinoma of the Pancreas or Gallbladder (University of Chicago IRB #16866-B)
2. A feasibility study of oral hormonal therapy and radiation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with medical comorbidities (University of Chicago IRB#10625-B)
3. A pilot study of Stereotactic Body Radiation Therapy in oligometastatic renal cell carcinoma (University of Chicago IRB#14-1542)